Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer

doi:10.19401/j.cnki.1007-3639.2022.11.002

Abstract

Abstract:

Ovarian cancer is one of the most common and lethal diseases among females. Due to the difficulty of surveillance and early detection, most ovarian cancers were diagnosed at advanced stage with poor outcomes. Epidemiological studies indicate that women with deleterious gene mutations have higher susceptibility of ovarian cancer. Thus, it is pivotal to prevent its occurrence. Risk-reducing salpingo-oophorectomy is the most effective method to prevent women at high risk from ovarian cancer. It depends on the standardization of the surgical and pathological procedure. In this article, we aimed to elucidate the current status and controversy of this risk-reducing surgery.

Key words: Ovarian cancer, Risk-reducing salpingo-oophorectomy, Hereditary ovarian cancer

CLC Number:

R737.31

FENG Zheng, WEN Hao. Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer[J]. China Oncology, 2022, 32(11): 1044-1048.

References 30

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[3]	BEREK J S, KEHOE S T, KUMAR L, et al. Cancer of the ovary, fallopian tube, and peritoneum[J]. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet, 2018, 143(Suppl 2): 59-78.
[4]	SOWTER H M, ASHWORTH A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes[J]. Carcinogenesis, 2005, 26(10): 1651-1656. doi: 10.1093/carcin/bgi136
[5]	MAVADDAT N, PEOCK S, FROST D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE[J]. J Natl Cancer Inst, 2013, 105(11): 812-822. doi: 10.1093/jnci/djt095
[6]	HALL M J, OBEID E I, SCHWARTZ S C, et al. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond[J]. Gynecol Oncol, 2016, 140(3): 565-574. doi: 10.1016/j.ygyno.2016.01.019
[7]	PENNINGTON K P, WALSH T, HARRELL M I, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas[J]. Clin Cancer Res, 2014, 20(3): 764-775. doi: 10.1158/1078-0432.CCR-13-2287 pmid: 24240112
[8]	DALY M B, PAL T, BERRY M P, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(1): 77-102. doi: 10.6004/jnccn.2021.0001
[9]	KURMAN R J, SHIH I M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory[J]. Am J Surg Pathol, 2010, 34(3): 433-443. doi: 10.1097/PAS.0b013e3181cf3d79 pmid: 20154587
[10]	ACOG committee opinion no. 774: opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention[J]. Obstet Gynecol, 2019, 133(4): e279-e284. doi: 10.1097/AOG.0000000000003164
[11]	DOMINGUEZ-VALENTIN M, SAMPSON J R, SEPPÄLÄ T T, et al. Cancer risks by gene, age, and gender in 6 350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database[J]. Genet Med, 2020, 22(1): 15-25.
[12]	SONG H L, DICKS E M, TYRER J, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer[J]. J Med Genet, 2021, 58(5): 305-313. doi: 10.1136/jmedgenet-2019-106739
[13]	WU N Y Y, FANG C, HUANG H S, et al. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions[J]. Mod Pathol, 2020, 33(1): 29-37. doi: 10.1038/s41379-019-0370-1
[14]	SHU C A, PIKE M C, JOTWANI A R, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations[J]. JAMA Oncol, 2016, 2(11): 1434-1440. doi: 10.1001/jamaoncol.2016.1820
[15]	STEENBEEK M P, HARMSEN M G, HOOGERBRUGGE N, et al. Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: a nonrandomized controlled trial[J]. JAMA Oncol, 2021, 7(8): 1203-1212. doi: 10.1001/jamaoncol.2021.1590
[16]	MEDEIROS F, MUTO M G, LEE Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome[J]. Am J Surg Pathol, 2006, 30(2): 230-236. pmid: 16434898
[17]	FOLKINS A K, JARBOE E A, SALEEMUDDIN A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations[J]. Gynecol Oncol, 2008, 109(2): 168-173. doi: 10.1016/j.ygyno.2008.01.012
[18]	VISVANATHAN K, SHAW P, MAY B J, et al. Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter study[J]. Cancer Prev Res (Phila), 2018, 11(11): 697-706. doi: 10.1158/1940-6207.CAPR-18-0009
[19]	AKAHANE T, MASUDA K, HIRASAWA A, et al. TP53 variants in p53 signatures and the clonality of STICs in RRSO samples[J]. J Gynecol Oncol, 2022, 33(4): e50. doi: 10.3802/jgo.2022.33.e50 pmid: 35557033
[20]	LÕHMUSSAAR K, KOPPER O, KORVING J, et al. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids[J]. Nat Commun, 2020, 11(1): 2660. doi: 10.1038/s41467-020-16432-0 pmid: 32461556
[21]	VAN DER HOEVEN N M A, VAN WIJK K, BONFRER S E, et al. Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review[J]. Clin Oncol (R Coll Radiol), 2018, 30(8): 463-471. doi: S0936-6555(18)30209-7 pmid: 29691126
[22]	PATRONO M G, INIESTA M D, MALPICA A, et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review[J]. Gynecol Oncol, 2015, 139(3): 568-572. doi: 10.1016/j.ygyno.2015.09.018 pmid: 26407480
[23]	CHENG A S, LI L, WU M, et al. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2020, 46(1): 139-147. doi: 10.1016/j.ejso.2019.09.002
[24]	RUSH S K, SWISHER E M, GARCIA R L, et al. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: a large prospective single institution experience[J]. Gynecol Oncol, 2020, 157(2): 514-520. doi: S0090-8258(20)30101-3 pmid: 32199636
[25]	SHERMAN M E, PIEDMONTE M, MAI P L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199[J]. J Clin Oncol, 2014, 32(29): 3275-3283. doi: 10.1200/JCO.2013.54.1987 pmid: 25199754
[26]	DOWDY S C, STEFANEK M, HARTMANN L C. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy[J]. Am J Obstet Gynecol, 2004, 191(4): 1113-1123. pmid: 15507929
[27]	STEENBEEK M P, VAN BOMMEL M H D, BULTEN J, et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis[J]. J Clin Oncol, 2022, 40(17): 1879-1891. doi: 10.1200/JCO.21.02016
[28]	VAN WINDEN L J, VERMEULEN R F M, VAN DEN NOORT V, et al. Changes in sex steroids and relation with menopausal complaints in women undergoing risk-reducing salpingo-oophorectomy[J]. J Endocr Soc, 2022, 6(6): bvac069. doi: 10.1210/jendso/bvac069
[29]	MOSS K M, MISHRA G D, KREJANY E O, et al. What happens after menopause? (WHAM): a prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy[J]. Gynecol Oncol, 2022, 167(1): 58-64. doi: 10.1016/j.ygyno.2022.07.029
[30]	MAI P L, MILLER A, BLACK A, et al. Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study[J]. Am J Obstet Gynecol, 2022, 227(1): 61. e1-61.61.e18.